|
Rockwell commences PRIME study of dialysate-added iron. |
|
|
|
Trading Markets: The PRIME study, a nine-month, prospective, randomized, placebo-controlled, double-blinded, multi-center study will randomize 100 patients equally to dialysate containing SFP-iron versus conventional dialysate
|